Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Sema4 in pact with Janssen re oncology trials

Sema4 has entered into a research agreement with Janssen Research & Development to optimize oncology clinical trials. Sema4 will provide Janssen access to two of...

| By Kelley Gipson

Yale designates SalivaDirect™ COVID labs in 3 states

Yale University has designated three independent laboratories to perform the university-developed SalivaDirect™ COVID-19 test. Along with Yale Pathology Labs — the first to offer the test...

| By Kelley Gipson

Biohaven reports progress on drugs

Biohaven is in late-stage human testing of a nasal spray version of its migraine drug zavegepant (formerly vazegepant) … more Earlier this year the company reported that it had...

| By Kelley Gipson

ReNetX adds Dr. Kevin Malobisky to SAB

ReNetX Bio has added Dr. Kevin Malobisky to its Scientific Advisory Board. Dr. Malobisky, currently the Chief Regulatory and Strategic Operations Officer at Tavanta Therapeutics, brings over...

| By Kelley Gipson

Shoreline Biome receives patent for lysis method

Shoreline Biome was recently awarded a patent for the “Combined Lysis Protocol for Comprehensive Cell Lysis.” The patent outlines the method and materials for the lysis of...

| By Kelley Gipson

The Yale Engage Cancer Series kicks off on 10/21

Yale Engage, in conjunction with the Yale Cancer Center, presents the Yale Engage Cancer Series, an interactive webinar series, promoting impactful collaboration between academic experts...

| By Kelley Gipson

2020 Entrepreneur of the Year nominations open

BioCT invites your nominations for the 2020 Entrepreneur of the Year Award. The Entrepreneur of the Year Award was established by BioCT and Shipman and...